← Back to Screener
Anbio Biotechnology Class A Ordinary Shares (NNNN)
Price$27.24
Favorite Metrics
Price vs S&P 500 (26W)-8.99%
Price vs S&P 500 (4W)9.83%
Market Capitalization$3.88B
P/E Ratio (Annual)606.26x
All Metrics
P/CF (Annual)1994.73x
Book Value / Share (Quarterly)$0.21
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-28.39%
Cash Flow / Share (Quarterly)$0.01
Price vs S&P 500 (YTD)-14.21%
Gross Margin (TTM)89.00%
Net Profit Margin (TTM)77.10%
EPS (TTM)$0.23
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$0.23
EPS (Annual)$0.15
ROI (Annual)21.24%
Gross Margin (Annual)87.24%
Net Profit Margin (5Y Avg)47.28%
Cash / Share (Quarterly)$0.08
P/E Basic Excl Extra (TTM)380.56x
Revenue Growth QoQ (YoY)5.64%
P/E Normalized (Annual)606.26x
ROA (Last FY)21.17%
Revenue Growth TTM (YoY)-5.72%
EBITD / Share (TTM)$0.21
ROE (5Y Avg)46.01%
Operating Margin (TTM)69.04%
Cash Flow / Share (Annual)$-0.05
P/B Ratio128.74x
P/B Ratio (Quarterly)143.49x
Net Income / Employee (Annual)$0
Net Interest Coverage (TTM)44.91x
ROA (TTM)35.22%
EPS Growth QoQ (YoY)161.32%
EPS Incl Extra (Annual)$0.15
Current Ratio (Annual)344.29x
Quick Ratio (Quarterly)177.11x
3-Month Avg Trading Volume0.05M
52-Week Price Return308.17%
EV / Free Cash Flow (Annual)1992.16x
P/E Incl Extra (TTM)380.56x
Revenue / Employee (TTM)$0
P/S Ratio (Annual)448.97x
Asset Turnover (Annual)0.29x
52-Week High$55.65
Operating Margin (5Y Avg)43.81%
EPS Excl Extra (Annual)$0.15
26-Week Price Return-2.10%
Quick Ratio (Annual)177.12x
13-Week Price Return-22.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)344.29x
Enterprise Value$3,874.418
Asset Turnover (TTM)0.46x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)74.06%
Cash / Share (Annual)$0.08
3-Month Return Std Dev132.47%
Gross Margin (5Y Avg)63.99%
Net Income / Employee (TTM)$0
ROE (Last FY)21.24%
EPS Basic Excl Extra (Annual)$0.15
P/FCF (TTM)1866.09x
Receivables Turnover (TTM)5.61x
EV / Free Cash Flow (TTM)1862.35x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.23
Receivables Turnover (Annual)3.66x
ROI (TTM)35.36%
P/S Ratio (TTM)293.41x
Pretax Margin (5Y Avg)47.28%
Revenue / Share (Annual)$0.20
Price vs S&P 500 (52W)273.54%
P/E Ratio (TTM)380.56x
EPS Growth TTM (YoY)69.57%
Year-to-Date Return-10.28%
5-Day Price Return-6.45%
EPS Normalized (Annual)$0.15
ROA (5Y Avg)34.25%
Net Profit Margin (Annual)74.06%
Month-to-Date Return5.02%
EBITD / Share (Annual)$0.13
EPS Growth (3Y)-13.70%
Operating Margin (Annual)66.70%
P/CF (TTM)1866.09x
ROI (5Y Avg)46.01%
P/E Excl Extra (TTM)380.56x
EPS Basic Excl Extra (TTM)$0.23
P/B Ratio (Annual)143.49x
Pretax Margin (TTM)77.10%
Book Value / Share (Annual)$0.21
Price vs S&P 500 (13W)-24.38%
Beta2.32x
P/FCF (Annual)1866.09x
Revenue / Share (TTM)$0.30
ROE (TTM)35.36%
52-Week Low$6.05
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NNNNAnbio Biotechnology Class A Ordinary Shares | 293.41x | -5.72% | 89.00% | — | $27.24 |
IDXXIdexx Laboratories Inc | 10.72x | 10.42% | 61.80% | 14.28% | $570.81 |
LNTHLantheus Holdings, Inc | 3.55x | 0.50% | 61.10% | 40.71% | $83.16 |
CLDXCelldex Therapeutics, Inc | 1744.87x | -77.98% | 17.65% | — | $33.98 |
NEOGNeogen Corp | 2.39x | -3.91% | 45.20% | — | $9.57 |
NTLAIntellia Therapeutics, Inc | 26.55x | 16.92% | — | — | $15.53 |
QDELQuidelOrtho Corporation Common Stock | 0.32x | -1.89% | 46.67% | — | $12.70 |
MYGNMyriad Genetics Inc | 0.59x | -1.56% | 69.93% | — | $5.14 |
ACHVAchieve Life Sciences, Inc. | 12.70x | -89.25% | — | — | $4.03 |
TKNOAlpha Teknova, Inc. Common Stock | 3.87x | 7.35% | 33.17% | — | $3.18 |
IMDXInsight Molecular Diagnostics Inc. Common Stock | 31.65x | 115.58% | 56.97% | — | $3.74 |
About
Anbio Biotechnology is an in vitro diagnostics company offering laboratory, point-of-care, and at-home testing solutions across infectious diseases, oncology, cardiovascular health, and other clinical domains. Its product portfolio includes automated analyzers such as the AF-1200 fluorescence immunoassay and SHA-100 dry chemistry systems, along with rapid diagnostic kits for conditions including COVID-19, dengue, and hepatitis. The company generates revenue primarily from Europe, with significant presence in South America and Asia-Pacific.